Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

mFOLFIRINOX Versus mFOLFOX 6 as Adjuvant Treatment for High Risk Stage III (pT4N1/2 or pTanyN2) Colon Cancer: Multicenter, Open Labeled, Randomized, Phase II Study

NCT05179889 is registered in ClinicalTrials.gov with Chungnam National University Hospital as lead sponsor.

NCT NCT05179889
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05179889 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
mFOLFIRINOX Versus mFOLFOX 6 as Adjuvant Treatment for High Risk Stage III (pT4N1/2 or pTanyN2) Colon Cancer: Multicenter, Open Labeled, Randomized, Phase II Study
Lead sponsor
Chungnam National University Hospital
Phase
Phase 2/3
Overall status
Recruiting
Start date
July 6, 2021
Completion date
March 15, 2031
Enrollment
308 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colon cancer stage iii